Skip to main content

Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? “Absolutely”, says expert Menzo Havenga (CEO, Batavia Biosciences). In an interview with a Dutch local newspaper, Menzo explains some of the benefits of the use of viral vectors, such as the stability and costs. Additionally, viral vectors have other highly promising medical applications like the development of cancer vaccines and gene therapies.

Link to article (in Dutch)